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Background
Maturity-Onset Diabetes of the Young (MODY) is the
most common form of monogenic diabetes. Genetic
analysis is required to confirm the diagnosis. Conven-
tional genetic testing uses Sanger sequencing. Currently,
Next-generation sequencing (NGS) has proven to be
cost-effective. To date, there is no NGS study for
MODY in Brazil.
Objective
To validate a new assay for molecular diagnosis of
MODY using targeted-NGS.
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Figure 1 Mutations identified by NGS in Brazilian subjects with MODY phenotype.
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Materials and methods
We have completed a pilot project including 7 unrelated
subjects with MODY phenotype. Genetic sequencing was
performed using Illumina NGS platform (MiSeq), allowing
analysis of 13 MODY genes simultaneously. All exonic
and intronic regions of these genes were evaluated. Two
cases were not tested before. In other 5 cases, a previous
analysis using Sanger sequencing of GCK and HNF1A
genes had been done. Three subjects had already a genetic
diagnosis of MODY by Sanger method and were selected
to validate NGS Results. And the other 2 cases had typical
clinical features but negative Sanger analysis.
Results
In all 7 cases analyzed, NGS was able to detect the
mutations related to MODY, and in those 2 previous
negative Sanger sequencing, it has allowed us to confirm
the diagnosis of this type of diabetes (Figure 1). Consider-
ing these 2 negative Sanger cases, one had a mild hyper-
glycemia detected at 15 yo, non-progressive during 4 yrs.
of follow-up, normal C-peptide, negative beta cell antibo-
dies, and also a family history of similar phenotype.
Previous Sanger testing for GCK had yielded a false nega-
tive result, because the mutation was a large deletion
located at the end of the last exon of GCK, which impaired
the analysis by Sanger, however was detected by NGS. The
second negative Sanger subject had diabetes since 8 yo,
low BMI, negative antibodies, detectable fasting C-peptide,
and a mother with asymptomatic hyperglycemia. This
patient had been using sulfonylurea with good glycemic
control. Sanger sequencing for HNF1A was negative. NGS
identified a mutation in GCK, already described in the lit-
erature as pathogenic.
Conclusions
In our pilot project, targeted-NGS was able to confirm
MODY diagnosis in all cases submitted to Sanger sequen-
cing (3 positive controls and 2 previously negative cases).
In other two not tested before, this new method could
identify the pathogenic variants. Thus, NGS can be consid-
ered an effective tool for diagnosing clinical suspicious
cases of MODY, appearing to be a promising technique.
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